(NASDAQ:FLXN) in a research note published on Friday. Given the stock's recent action, it seemed like a good time to take a closer look at the company's recent data.
According to the latest research reports released, 4 analysts have issued a rating of "buy", 4 analysts "outperform", 0 analysts "hold", 0 analysts "underperform" and 0 analysts "sell". Cantor Fitzgerald set a $40.00 price objective on shares of Flexion Therapeutics and gave the company a buy rating in a report on Monday, June 12th. As concerns shares volumes, in share Capital Company has 102.08 million outstanding shares among them 85.57 million shares have been floated in market exchange. Flexion Therapeutics had 18 analyst reports since July 31, 2015 according to SRatingsIntel. Now the stock price is moving -17.13% off from the highest level of twelve months and 8.46% above from twelve months low.
Traders are more bearish on shares of Flexion Therapeutics, Inc. of late looking at the change in short interest.
Flexion Therapeutics, Inc. (FLXN) now has a Return on Assets (ROA) value of -38.2 Percent. The company has a 50-day moving average of $24.68 and a 200-day moving average of $22.57. On Wednesday, October 4 the stock rating was maintained by Northland Capital with "Buy". Previously Flexion Therapeutics (NASDAQ:FLXN) reported $-0.91 earnings per share (EPS) for the quarter, missing the consensus estimate of $-0.82 by $-0.09 with surprise factor of -11%. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and worldwide trademark and copyright legislation. Royal Bank Of Canada reiterated an "outperform" rating and issued a $44.00 price target on shares of Flexion Therapeutics in a research note on Thursday, August 10th. In the past 3-month period alone, shares of FLXN have appreciated - or. The stock was acquired at an average cost of $24.15 per share, with a total value of $72,450.00. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company's stock valued at $103,000 after purchasing an additional 1,000 shares during the last quarter. Over the last three months, insiders have purchased 5,375 shares of company stock valued at $131,575. Investors measure stock performance on the basis of a company's earnings power. Wells Fargo & Company MN raised its holdings in shares of Flexion Therapeutics by 25.1% during the first quarter. Ardsley Advisory Partners bought a new stake in Flexion Therapeutics during the second quarter worth $3,338,000. Public Employees Retirement System of OH raised its position in Flexion Therapeutics by 69.4% during the second quarter. The stock was sold at an average price of $23.00, for a total value of $69,000.00. As of quarter end Raymond James Financial Services Advisors, Inc. had acquired 7,667 shares growing its holdings by 13.7%. Finally, The Manufacturers Life Insurance Company raised its position in Flexion Therapeutics by 3.9% during the second quarter.
The company is expected to report earnings of $-0.95 a share for the next quarter. It is positive, as 17 investors sold Flexion Therapeutics Inc shares while 17 reduced holdings. The Manufacturers Life Insurance Company now owns 21,802 shares of the specialty pharmaceutical company's stock worth $441,000 after acquiring an additional 811 shares in the last quarter.
On the other hand the company has Relative Strength Index (RSI 14) of 63.14 along with Average True Range (ATR 14) of 1.78, Consequently Flexion Therapeutics (NASDAQ:FLXN)'s weekly and monthly volatility is 10.87%, 6.01% respectively. The Company is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain.